The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
TERT promoter mutations in thyroid cancer
Open accessAbstract
The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5, 1,295,228 C>T (C228T) and 1,295,250 C>T (C250T) in thyroid cancer represents an important event in the thyroid cancer field and much progress has occurred since then. This article provides a comprehensive review of this exciting new thyroid cancer field. The oncogenic role of TERT promoter mutations involves their creation of consensus binding sites for E-twenty-six transcriptional factors. TERT C228T is far more common than TERT C250T and their collective prevalence is, on average, 0, 11.3, 17.1, 43.2 and 40.1% in benign thyroid tumors, papillary thyroid cancer (PTC), follicular thyroid cancer, poorly differentiated thyroid cancer and anaplastic thyroid cancer, respectively, displaying an association with aggressive types of thyroid cancer. TERT promoter mutations are associated with aggressive thyroid tumor characteristics, tumor recurrence and patient mortality as well as BRAF V600E mutation. Coexisting BRAF V600E and TERT promoter mutations have a robust synergistic impact on the aggressiveness of PTC, including a sharply increased tumor recurrence and patient mortality, while either mutation alone has a modest impact. Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g. RAS mutations), are proving to be clinically useful for the management of thyroid cancer. Future studies will specifically define such clinical utilities, elucidate the biological mechanisms and explore the potential as therapeutic targets of TERT promoter mutations in thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · cited 1×
“The combined OR was calculated by the fixed-effects model (the Mantel–Haenszel method) when between-study heterogeneity was absent (Mantel & Haenszel 1959); otherwise the random-effects model (the Dersimonian and Laird method) was used (Dersimonian & Laird 1986).”
MethodSEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“0) Landa et al. (2013) 2/16 (12.”
Background(2023) · doi:10.1126/science · Cited by 6,063
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“R e la te d C a n ce r Shay & Bacchetti 1997), which prevents the happening of critical telomere shortening, thus enabling cancer cells acquire replicative immortality (Hanahan & Weinberg 2011).”
BackgroundCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
A highly conserved repetitive DNA sequence,(TTAGGG) n, present at the telomeres of human chromosomes
Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., Jones, M. D., Meyne, J., Ratliff, R. L., & Wu, J. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6622 · Cited by 1,820
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
Telomeres and human disease: ageing, cancer and beyond
Blasco, M. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1656 · Cited by 1,434
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationMalard, F., Wolter, A. C., Marquevielle, J., Morvan, E., Ecoutin, A., Rüdisser, S. H., Allain, F. H. T., & Campagne, S. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae201 · Cited by 1,273
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Self-citationIdentification of seven loci affecting mean telomere length and their association with disease
CARDIoGRAM consortium, Codd, V., Nelson, C. P., Albrecht, E., Mangino, M., Deelen, J., Buxton, J. L., Hottenga, J. J., Fischer, K., Esko, T., et al. (2013) · Nature Genetics · doi:10.1038/ng.2528 · Cited by 933
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Self-citationHighly prevalent TERT promoter mutations in aggressive thyroid cancers
Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., Sun, H., El-Naggar, A. K., & Xing, M. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0210 · Cited by 613
Self-citationSequence variants at the TERT-CLPTM1L locus associate with many cancer types
Rafnar, T., Sulem, P., Stacey, S. N., Geller, F., Gudmundsson, J., Sigurdsson, A., Jakobsdottir, M., Helgadottir, H., Thorlacius, S., Aben, K. K. H., et al. (2009) · Nature Genetics · doi:10.1038/ng.296 · Cited by 609
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
Study, A. C., Bojesen, S. E., Study, A. O. C., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), (GENICA), G. E. I. A. B. C., (SWE-BRCA), S. B. C. S., The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), (EMBRACE), E. S. O. B. &. B. M. C., (GEMO), G. M. O. C. R. I. B. M. C., Pooley, K. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2566 · Cited by 528
(2019) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1200/jco · Cited by 522
Nikiforov, Y. E., Carty, S. E., Chiosea, S. I., Coyne, C., Duvvuri, U., Ferris, R. L., Gooding, W. E., Hodak, S. P., LeBeau, S. O., Ohori, N. P., et al. (2014) · Cancer · doi:10.1002/cncr.29038 · Cited by 500
Landa, I., Ganly, I., Chan, T. A., Mitsutake, N., Matsuse, M., Ibrahimpasic, T., Ghossein, R. A., & Fagin, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2383 · Cited by 462
Telomerase modulates expression of growth-controlling genes and enhances cell proliferation
Smith, L. L., Coller, H. A., & Roberts, J. M. (2003) · Nature Cell Biology · doi:10.1038/ncb985 · Cited by 438
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism
Stewart, S. A., Hahn, W. C., O'Connor, B. F., Banner, E. N., Lundberg, A. S., Modha, P., Mizuno, H., Brooks, M. W., Fleming, M., Zimonjic, D. B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182407599 · Cited by 431
Conditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., Artandi, M. K., Oro, A. E., & Artandi, S. E. (2005) · Nature · doi:10.1038/nature03836 · Cited by 425
Telomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378
González‐Suárez, E., Samper, E., Ramírez, A., Flores, J. M., Martín‐Caballero, J., Jorcano, J. L., & Blasco, M. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2619 · Cited by 372
Choi, J., Southworth, L. K., Sarin, K. Y., Venteicher, A. S., Ma, W., Chang, W., Cheung, P., Jun, S., Artandi, M. K., Shah, N., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.0040010 · Cited by 336
Telomeres and telomerase in aging and cancer
Harley, C. (1995) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(95)80016-6 · Cited by 324
Liu, X., Qu, S., Liu, R., Sheng, C., Shi, X., Zhu, G., Murugan, A. K., Guan, H., Yu, H., Wang, Y., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4048 · Cited by 318
Self-citationGenetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Xing, M. (2010) · Thyroid · doi:10.1089/thy.2010.1646 · Cited by 305
Self-citationTelomerase: central regulator of all of the hallmarks of cancer
Low, K. C., & Tergaonkar, V. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.07.001 · Cited by 257
TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
Griewank, K. G., Murali, R., Puig-Butille, J. A., Schilling, B., Livingstone, E., Potrony, M., Carrera, C., Schimming, T., Möller, I., Schwamborn, M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju246 · Cited by 254
Liu, T., Wang, N., Cao, J., Sofiadis, A., Dinets, A., Zedenius, J., Larsson, C., & Xu, D. (2014) · Oncogene · doi:10.1038/onc.2013.446 · Cited by 251
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
Simon, M., Hosen, I., Gousias, K., Rachakonda, S., Heidenreich, B., Gessi, M., Schramm, J., Hemminki, K., Waha, A., & Kumar, R. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou158 · Cited by 237
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
Shi, X., Liu, R., Basolo, F., Giannini, R., Shen, X., Teng, D., Guan, H., Shan, Z., Teng, W., Musholt, T. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2917 · Cited by 203
Self-citationThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
Saji, M., & Ringel, M. D. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.016 · Cited by 190
InTERTpreting telomerase structure and function
Wyatt, H. D. M., West, S. C., & Beattie, T. L. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq370 · Cited by 184
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 168
Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity
Koh, C. M., Khattar, E., Leow, S. C., Liu, C. Y., Muller, J., Ang, W. X., Li, Y., Franzoso, G., Li, S., Guccione, E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79134 · Cited by 162
Hrdličková, R., Nehyba, J., & Bose, H. R. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00550-12 · Cited by 147
Nitti, D., BELLUCO, C., FASSINA, A., Ninfo, V., LISE, M., MC, M., R, B., & P, D. P. (1998) · Padua Research Archive (University of Padova) · doi:10.1016/s0959-8049 · Cited by 146
TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma
Gandolfi, G., Ragazzi, M., Frasoldati, A., Piana, S., Ciarrocchi, A., & Sancisi, V. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0837 · Cited by 141
On the road to immortality: hTERT upregulation in cancer cells
Janknecht, R. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00356-4 · Cited by 135
Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid
Chindris, A.-M., Casler, J. D., Bernet, V. J., Rivera, M., Thomas, C., Kachergus, J. M., Necela, B. M., HAY, I. D., Westphal, S. A., Grant, C. S., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1634 · Cited by 135
Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma
Liu, X., Wu, G., Shan, Y., Hartmann, C. J., von Deimling, A., & Xing, M. (2013) · Cell Cycle · doi:10.4161/cc.24662 · Cited by 132
Self-citationWang, N., Liu, T., Sofiadis, A., Juhlin, C. C., Zedenius, J., Höög, A., Larsson, C., & Xu, D. (2014) · Cancer · doi:10.1002/cncr.28800 · Cited by 123
Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.
Umbricht, C. B., Saji, M., Westra, W. H., Udelsman, R., Zeiger, M. A., & Sukumar, S. V. (1997) · PubMed · Cited by 115
Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization
Muzza, M., Colombo, C., Rossi, S., Tosi, D., Cirello, V., Perrino, M., Leo, S. D., Magnani, E., Pignatti, E., Vigo, B., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.019 · Cited by 113
Wang, Z., Zhu, B., Zhang, M., Parikh, H. M., Jia, J., Chung, C. C., Sampson, J. N., Hoskins, J. W., Hutchinson, A. A., Burdette, L. A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu363 · Cited by 111
TERT Promoter Mutations in Papillary Thyroid Microcarcinomas
de Biase, D., Gandolfi, G., Ragazzi, M., Eszlinger, M., Sancisi, V., Gugnoni, M., Visani, M., Pession, A., Casadei, G. P., Durante, C., et al. (2015) · Thyroid · doi:10.1089/thy.2015.0101 · Cited by 106
BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression
Nucera, C., Lawler, J., & Parangi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3844 · Cited by 101
Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms.
Saji, M., Xydas, S., Westra, W. H., Liang, C. K., Clark, D. P., Udelsman, R., Umbricht, C. B., Sukumar, S. V., & Zeiger, M. A. (1999) · PubMed · Cited by 98
Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy
Liu, R., & Xing, M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0359 · Cited by 96
Self-citationShi, X., Liu, R., Qu, S., Zhu, G., Bishop, J. A., Liu, X., Sun, H., Shan, Z., Wang, E., Luo, Y., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3606 · Cited by 87
Self-citationTall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT
Dettmer, M. S., Schmitt, A. M., Steinert, H. C., Capper, D., Moch, H., Komminoth, P., & Perren, A. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0057 · Cited by 84
Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions
Ballester, L. Y., Sarabia, S. F., Sayeed, H., Patel, N. R., Baalwa, J., Athanassaki, I. D., Hernandez, J. A., Fang, E., Quintanilla, N., Roy, A., et al. (2015) · Pediatric and Developmental Pathology · doi:10.2350/15-05-1638-oa.1 · Cited by 68
TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population
Qasem, E., Murugan, A. K., Al‐Hindi, H., Xing, M., Almohanna, M., Alswailem, M. M., & Alzahrani, A. S. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0396 · Cited by 54
Self-citationWang, N., Xu, D., Sofiadis, A., Höög, A., Vukojević, V. B., Bäckdahl, M., Zedenius, J., & Larsson, C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1158 · Cited by 44
Greider, C. W., & Blackburn, E. H. (2004) · Cell · doi:10.1016/s0092-8674(04)00053-4 · Cited by 43
Crescenzi, A., Trimboli, P., Modica, D. C., Taffon, C., Guidobaldi, L., Taccogna, S., Rainer, A., Trombetta, M., Papini, E., & Zelano, G. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1548873 · Cited by 29
Ito, Y., Yoshida, H., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Kuma, K., & Miyauchi, A. (2005) · PubMed · Cited by 27
TERT and BRAF in Thyroid Cancer: Teaming Up for Trouble
Ngeow, J. Y. Y., & Eng, C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5614 · Cited by 21
Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications
Nucera, C. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00167 · Cited by 13
Asaad, N. Y., El‐Wahed, M. M. A., & Ag, M. (2006) · PubMed · Cited by 10
Cited by
Steward, D. L., Carty, S. E., Sippel, R. S., Yang, S. P., Sosa, J. A., Sipos, J. A., Figge, J. J., Mandel, S., Haugen, B. R., Burman, K. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4616 · Cited by 486
Liu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
Self-citationYoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
Leão, R., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U., & Castelo-Branco, P. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0422-8 · Cited by 265
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
Metadata
- Authors
- Liu, R., & Xing, M.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2016-01-05
- Volume
- 23
- Issue
- 3
- Pages
- R143-R155
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2225849677
- Cited by
- 441
- References
- 80
- FWCI
- 36.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.